# Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

> **NCT06633341** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- T-lymphoblastic Lymphoma

## Interventions

- **BIOLOGICAL:** CD5 CAR T-cells

## Key facts

- **NCT ID:** NCT06633341
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-20
- **Primary completion:** 2027-10-20
- **Final completion:** 2027-10-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06633341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06633341, "Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06633341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*